Intermed Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 33.45 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit 1259.38%
(FY 2023)
- Ebitda 1847.81%
(FY 2023)
- Net Worth 1171.10%
(FY 2023)
- Total Assets 135.72%
(FY 2023)
About Intermed Laboratories
The Corporate was formerly known as Intermed Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹33.45 Cr.
Paresh Kirtilal, Riddhi Javeri, and Rushabh Mehta serve as directors at the Company.
- CIN/LLPIN
U24230MH2019PTC331617
- Company No.
331617
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Oct 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Intermed Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Paresh Kirtilal  | Director | 10-Aug-2021 | Current |
| Riddhi Javeri | Director | 14-Oct-2019 | Current |
| Rushabh Mehta | Director | 24-Aug-2021 | Current |
Financial Performance of Intermed Laboratories.
Intermed Laboratories Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 1259.38% increase in profit. The company's net worth Soared by an impressive increase of 1171.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Intermed Laboratories?
In 2023, Intermed Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Intermed Life Sciences Private LimitedActive 1 year 1 monthParesh Kirtilal, Riddhi Javeri and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 29 Oct 2021 | ₹33.45 Cr | Open |
How Many Employees Work at Intermed Laboratories?
Intermed Laboratories has a workforce of 195 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Intermed Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Intermed Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
